安科生物
(300009)
| 流通市值：96.25亿 | | | 总市值：130.64亿 |
| 流通股本：12.31亿 | | | 总股本：16.71亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,652,239,532.19 | 1,097,894,716.88 | 541,715,939.09 | 2,646,519,767.58 |
| 营业收入 | 1,652,239,532.19 | 1,097,894,716.88 | 541,715,939.09 | 2,646,519,767.58 |
| 二、营业总成本 | 1,117,910,857.92 | 723,615,315.46 | 352,814,069.35 | 1,835,649,613.89 |
| 营业成本 | 405,613,232.53 | 265,522,219.21 | 132,230,483.02 | 643,158,185.54 |
| 税金及附加 | 15,833,777.46 | 10,567,662.09 | 5,106,701.74 | 22,579,554.18 |
| 销售费用 | 475,631,038.12 | 298,761,799.86 | 145,987,437.14 | 797,023,675.17 |
| 管理费用 | 109,268,478.48 | 70,848,367.32 | 33,815,825.82 | 150,904,536.74 |
| 研发费用 | 111,901,725.61 | 77,946,110.76 | 36,039,441.22 | 219,446,120.51 |
| 财务费用 | -337,394.28 | -30,843.78 | -365,819.59 | 2,537,541.75 |
| 其中:利息费用 | 1,515,226.81 | 780,124.59 | 110,160.36 | 1,934,682.41 |
| 其中:利息收入 | 2,385,413.84 | 1,105,395.57 | 467,024.45 | 3,480,666.32 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 7,052,882.85 | 3,319,536.98 | 4,161,698.81 | 1,881,347.93 |
| 加:投资收益 | 3,385,525.39 | 7,238,901.06 | 831,706.02 | 18,203,718.45 |
| 资产处置收益 | 1,044,807.08 | 149,780.75 | 0 | 6,301,460.04 |
| 资产减值损失(新) | -1,263,308.99 | -1,267,065.92 | 0 | -17,471,471.06 |
| 信用减值损失(新) | -1,992,329.43 | 2,132,114.59 | -218,358.35 | -10,574,169.32 |
| 其他收益 | 9,988,738.56 | 6,036,941.94 | 3,572,373.8 | 27,750,020.12 |
| 四、营业利润 | 552,544,989.73 | 391,889,610.82 | 197,249,290.02 | 836,961,059.85 |
| 加:营业外收入 | 26,216.75 | 20,754.15 | 31,690.99 | 57,733.4 |
| 减:营业外支出 | 1,676,648.43 | 1,522,743.39 | 150,059.38 | 3,860,692.06 |
| 五、利润总额 | 550,894,558.05 | 390,387,621.58 | 197,130,921.63 | 833,158,101.19 |
| 减:所得税费用 | 72,255,630.05 | 50,081,716.94 | 24,966,174.55 | 85,819,395.5 |
| 六、净利润 | 478,638,928 | 340,305,904.64 | 172,164,747.08 | 747,338,705.69 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 478,638,928 | 340,305,904.64 | 172,164,747.08 | 747,338,705.69 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 467,952,882.76 | 332,330,541.08 | 167,587,671.9 | 735,192,705.68 |
| 少数股东损益 | 10,686,045.24 | 7,975,363.56 | 4,577,075.18 | 12,146,000.01 |
| 扣除非经常损益后的净利润 | 448,272,165.46 | 318,866,647.09 | 159,363,883.19 | 668,054,957.26 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.28 | 0.2 | 0.1 | 0.44 |
| (二)稀释每股收益 | 0.28 | 0.2 | 0.1 | 0.44 |
| 八、其他综合收益 | -242,328,072.54 | -220,259,779.45 | 22,265,954.79 | 64,761,046.22 |
| 归属于母公司股东的其他综合收益 | -242,328,072.54 | -220,259,779.45 | 22,265,954.79 | 64,761,046.22 |
| 九、综合收益总额 | 236,310,855.46 | 120,046,125.19 | 194,430,701.87 | 812,099,751.91 |
| 归属于母公司股东的综合收益总额 | 225,624,810.22 | 112,070,761.63 | 189,853,626.69 | 799,953,751.9 |
| 归属于少数股东的综合收益总额 | 10,686,045.24 | 7,975,363.56 | 4,577,075.18 | 12,146,000.01 |
| 公告日期 | 2026-10-24 | 2026-08-26 | 2026-04-24 | 2026-03-31 |
| 审计意见(境内) | | | | 标准无保留意见 |